These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 33351104)

  • 1. Constitutive activation of Lyn kinase enhances BCR responsiveness, but not the development of CLL in Eµ-TCL1 mice.
    Kohlhas V; Hallek M; Nguyen PH
    Blood Adv; 2020 Dec; 4(24):6106-6116. PubMed ID: 33351104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lessons learned from the Eµ-TCL1 mouse model of CLL.
    Floerchinger A; Seiffert M
    Semin Hematol; 2024 Jun; 61(3):194-200. PubMed ID: 38839457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B-cell antigen receptor expression and phosphatidylinositol 3-kinase signaling regulate genesis and maintenance of mouse chronic lymphocytic leukemia.
    Schmid VK; Khadour A; Ahmed N; Brandl C; Nitschke L; Rajewsky K; Jumaa H; Hobeika E
    Haematologica; 2022 Aug; 107(8):1796-1814. PubMed ID: 35021605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia.
    Herling M; Patel KA; Weit N; Lilienthal N; Hallek M; Keating MJ; Jones D
    Blood; 2009 Nov; 114(21):4675-86. PubMed ID: 19770358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Eμ- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling.
    Suljagic M; Longo PG; Bennardo S; Perlas E; Leone G; Laurenti L; Efremov DG
    Blood; 2010 Dec; 116(23):4894-905. PubMed ID: 20716772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two types of BCR interactions are positively selected during leukemia development in the Eμ-TCL1 transgenic mouse model of CLL.
    Iacovelli S; Hug E; Bennardo S; Duehren-von Minden M; Gobessi S; Rinaldi A; Suljagic M; Bilbao D; Bolasco G; Eckl-Dorna J; Niederberger V; Autore F; Sica S; Laurenti L; Wang H; Cornall RJ; Clarke SH; Croce CM; Bertoni F; Jumaa H; Efremov DG
    Blood; 2015 Mar; 125(10):1578-88. PubMed ID: 25564405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the LYN/HS1 signaling axis in chronic lymphocytic leukemia.
    ten Hacken E; Scielzo C; Bertilaccio MT; Scarfò L; Apollonio B; Barbaglio F; Stamatopoulos K; Ponzoni M; Ghia P; Caligaris-Cappio F
    Blood; 2013 Mar; 121(12):2264-73. PubMed ID: 23325840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel role of prostate apoptosis response-4 tumor suppressor in B-cell chronic lymphocytic leukemia.
    McKenna MK; Noothi SK; Alhakeem SS; Oben KZ; Greene JT; Mani R; Perry KL; Collard JP; Rivas JR; Hildebrandt GC; Fleischman RA; Durbin EB; Byrd JC; Wang C; Muthusamy N; Rangnekar VM; Bondada S
    Blood; 2018 Jun; 131(26):2943-2954. PubMed ID: 29695515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal analyses of CLL in mice identify leukemia-related clonal changes including a Myc gain predicting poor outcome in patients.
    Öztürk S; Paul Y; Afzal S; Gil-Farina I; Jauch A; Bruch PM; Kalter V; Hanna B; Arseni L; Roessner PM; Schmidt M; Stilgenbauer S; Dietrich S; Lichter P; Zapatka M; Seiffert M
    Leukemia; 2022 Feb; 36(2):464-475. PubMed ID: 34417556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PTPROt-mediated regulation of p53/Foxm1 suppresses leukemic phenotype in a CLL mouse model.
    Motiwala T; Kutay H; Zanesi N; Frissora FW; Mo X; Muthusamy N; Jacob ST
    Leukemia; 2015 Jun; 29(6):1350-9. PubMed ID: 25482129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of extracellular signal-regulated kinase through B-cell antigen receptor in B-cell chronic lymphocytic leukemia.
    Kawauchi K; Ogasawara T; Yasuyama M
    Int J Hematol; 2002 Jun; 75(5):508-13. PubMed ID: 12095152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-181b as a therapeutic agent for chronic lymphocytic leukemia in the Eµ-TCL1 mouse model.
    Bresin A; Callegari E; D'Abundo L; Cattani C; Bassi C; Zagatti B; Narducci MG; Caprini E; Pekarsky Y; Croce CM; Sabbioni S; Russo G; Negrini M
    Oncotarget; 2015 Aug; 6(23):19807-18. PubMed ID: 26090867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells.
    Petlickovski A; Laurenti L; Li X; Marietti S; Chiusolo P; Sica S; Leone G; Efremov DG
    Blood; 2005 Jun; 105(12):4820-7. PubMed ID: 15728130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Distinct Unmutated Chronic Lymphocytic Leukemia Subsets in Mice Based on Their T Cell Dependency.
    Pal Singh S; de Bruijn MJW; de Almeida MP; Meijers RWJ; Nitschke L; Langerak AW; Pillai SY; Stadhouders R; Hendriks RW
    Front Immunol; 2018; 9():1996. PubMed ID: 30271400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD19 amplifies B lymphocyte signal transduction by regulating Src-family protein tyrosine kinase activation.
    Fujimoto M; Poe JC; Jansen PJ; Sato S; Tedder TF
    J Immunol; 1999 Jun; 162(12):7088-94. PubMed ID: 10358152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ROR1 can interact with TCL1 and enhance leukemogenesis in Eμ-TCL1 transgenic mice.
    Widhopf GF; Cui B; Ghia EM; Chen L; Messer K; Shen Z; Briggs SP; Croce CM; Kipps TJ
    Proc Natl Acad Sci U S A; 2014 Jan; 111(2):793-8. PubMed ID: 24379361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia.
    Walker JS; Hing ZA; Harrington B; Baumhardt J; Ozer HG; Lehman A; Giacopelli B; Beaver L; Williams K; Skinner JN; Cempre CB; Sun Q; Shacham S; Stromberg BR; Summers MK; Abruzzo LV; Rassenti L; Kipps TJ; Parikh S; Kay NE; Rogers KA; Woyach JA; Coppola V; Chook YM; Oakes C; Byrd JC; Lapalombella R
    J Hematol Oncol; 2021 Jan; 14(1):17. PubMed ID: 33451349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.
    Till KJ; Pettitt AR; Slupsky JR
    J Immunol; 2015 Mar; 194(5):2439-46. PubMed ID: 25632006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD74 is dispensable for development of chronic lymphocytic leukemia in
    Barthel R; Fedorchenko O; Velmans T; Rosen N; Nguyen PH; Reinart N; Florin A; Herling M; Hallek M; Fingerle-Rowson G
    Leuk Lymphoma; 2020 Dec; 61(12):2799-2810. PubMed ID: 32667245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Par-4 overexpression impedes leukemogenesis in the Eµ-TCL1 leukemia model through downregulation of NF-κB signaling.
    Greene JT; Mani R; Ramaswamy R; Frissora F; Yano M; Zapolnik K; Harrington B; Wasmuth R; Tran M; Mo X; McKenna M; Rangnekar VM; Byrd JC; Bondada S; Muthusamy N
    Blood Adv; 2019 Apr; 3(8):1255-1266. PubMed ID: 30987970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.